FDA Approves Inspire Therapy Expansion for Specific Pediatric Population
Inspire intends to immediately begin educating healthcare providers across the US about the benefits of Inspire therapy for this population of children.
Tag: Inspire Medical
All
Latest
All
Latest
EnsoData Raises $20M, Which Will Help the Company Accelerate the Adoption of AI Technology Across Healthcare
EnsoData will accelerate expansion and commercial distribution partnerships, continue building its team, and expand its offerings.
All
Latest
FDA Approves Inspire Medical’s New Physician Programmer Platform
A new telemetry cable enables Bluetooth connectivity to the programmer tablet. The platform interfaces with Inspire Cloud.
Neurostimulators Expand Opportunities for Sleep Practices
A second chance for many patients, devices like Inspire and remede also facilitate new avenues for marketing.
Read More
Inspire Launches Patient Experience Report
Inspire’s core objective with this report is to allow its customers to make informed decisions related to the best treatment options.
Read MoreMedicare Panel Recommends Increasing Payments for Inspire Therapy to Ambulatory Surgical Centers
CMS will review the panel’s recommendations, and the final rules will be published later in 2021.
Read More
CPAP Alternatives: Sleep Center Personalizes Treatment for Every Sleep Apnea Patient
A flow chart from Sleep 360 Sleep Diagnostic Center illustrates the OSA patient journey from referral to customized therapy.
Read More
How to Make Neurostimulator Acclimatization Easier for Patients
Many patients give up on CPAP because they can’t tolerate the machine. Implanted neurostimulators may help, but, like positive airway pressure, these new devices can take some getting used to.
Read MoreAnthem Issues Positive Coverage Policy for Inspire Therapy
This positive coverage decision provides additional OSA patients who are unable to benefit from CPAP the opportunity to gain access to Inspire therapy.”
Read More
New Distribution Agreement to Commercialize Inspire Therapy in Japan
Inspire and Japan Lifeline Co Ltd worked closely with the Minister of Health Labour and Welfare to advance the reimbursement application for Inspire therapy, which was approved by an expert panel this month.
Read More2020 Roundup: The Year in FDA Clearances & Approvals for Sleep Medicine
It’s been an unusual year. But, mostly as usual, the US Food & Drug Administration continued to review device and drug applications across all fields of medicine.
Read MoreMultidisciplinary Perspectives on OSA Treatment with Inspire for CPAP-intolerant Patients
Panelists discuss proper patient selection, preparation for device evaluation and the procedure, and post-implant adjustments.
Read More
After Two Decades, 73-Year-Old Finds Sleep Apnea Therapy That Works for Him
After more than 20 years of troubled sleep, Dwight Johnson can finally sleep peacefully throughout the night.
Read MoreHumana Now Provides Coverage for Inspire Upper Airway Stimulation
Health plan provider Humana Inc will provide coverage for Inspire upper airway stimulation therapy, effective August 27.
Read MoreInspire Therapy Gets Regulatory Approval in Australia
The reimbursement process is anticipated to be completed during 2021 and Inspire expects to launch its therapy in Australia thereafter.
Read More
Why I Choose Neurostimulators for Some of My Sleep Apnea Patients
Physicians who use Inspire upper airway stimulation, Respicardia’s remedē, and Avery’s diaphragm pacemaker share their stories.
Read More
Inspire Medical Launches Patient App for Its Upper Airway Stimulation Therapy
Inspire has multiple additional digital health solutions in development that are aimed at improving patient outcomes and medical practice efficiency.
Read MoreInspire Upper Airway Stimulation Therapy FDA Approved for 18- to 21-Year-Olds
The US Food and Drug Administration (FDA) has approved an expanded age range for Inspire Upper Airway Stimulation Therapy for obstructive sleep apnea to include 18-21 year old patients.
Read More